<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651949</url>
  </required_header>
  <id_info>
    <org_study_id>V503-003</org_study_id>
    <secondary_id>2012-002758-22</secondary_id>
    <nct_id>NCT01651949</nct_id>
  </id_info>
  <brief_title>Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)</brief_title>
  <official_title>A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV
      vaccine, V503) in 16- to 26-year old men and women. The overall goal is to bridge 9vHPV
      efficacy findings in young women to young men based on the demonstration of similar
      immunogenicity and safety profiles. The primary hypothesis is that 9vHPV induces antibody
      responses at 4 weeks postdose 3 in heterosexual males that are non-inferior to antibody
      responses in young women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will be administered a 3-dose regimen of 9vHPV. They will be assessed for
      immunogenicity 1 month following completion of vaccination. All participants will be followed
      for safety for a total of 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2012</start_date>
  <completion_date type="Actual">August 4, 2014</completion_date>
  <primary_completion_date type="Actual">August 4, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine</measure>
    <time_frame>Four weeks post vaccination 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Elevated Oral Body Temperature (&gt;=37.8° C, &gt;=100° F)</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Adverse Event</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine</measure>
    <time_frame>Four weeks post vaccination 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2520</enrollment>
  <condition>Genital Warts</condition>
  <condition>Anal Cancer</condition>
  <condition>Anal Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>Females</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterosexual Males</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Men who have Sex with Men</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9vHPV Vaccine</intervention_name>
    <description>9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen</description>
    <arm_group_label>Females</arm_group_label>
    <arm_group_label>Heterosexual Males</arm_group_label>
    <arm_group_label>Men who have Sex with Men</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good physical health

          -  Has never had Papanicolaou testing (Pap, cervical or anal) or has only had normal Pap
             test results

          -  Other inclusion criteria will be discussed with the investigator

        Exclusion Criteria:

          -  History of severe allergic reaction that required medical intervention

          -  Currently enrolled in a clinical trial

          -  If participant is female, pregnant

          -  Currently immunocompromised or having received immunosuppressive therapy in the last
             year

          -  Positive test for HPV

          -  History of HPV-related external genital lesions or HPV-related anal lesions or anal
             cancer

          -  If participant is female, history of abnormal cervical biopsy results

          -  Other exclusion criteria will be discussed with the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, Luxembourg A, Kaplan SS. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015 Nov 27;33(48):6892-901. doi: 10.1016/j.vaccine.2015.06.088. Epub 2015 Jul 2.</citation>
    <PMID>26144901</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <results_first_submitted>February 24, 2015</results_first_submitted>
  <results_first_submitted_qc>February 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2015</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=V503-003&amp;kw=V503-003&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Heterosexual Males</title>
          <description>Healthy heterosexual males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P2">
          <title>Females</title>
          <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P3">
          <title>Men Who Have Sex With Men (MSM)</title>
          <description>Healthy MSM 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1106"/>
                <participants group_id="P2" count="1101"/>
                <participants group_id="P3" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="1103"/>
                <participants group_id="P2" count="1099"/>
                <participants group_id="P3" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="1089"/>
                <participants group_id="P2" count="1069"/>
                <participants group_id="P3" count="298"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="1067"/>
                <participants group_id="P2" count="1037"/>
                <participants group_id="P3" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1053"/>
                <participants group_id="P2" count="1015"/>
                <participants group_id="P3" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unknown status</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heterosexual Males</title>
          <description>Healthy heterosexual males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>Females</title>
          <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>Men Who Have Sex With Men (MSM)</title>
          <description>Healthy MSM 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1106"/>
            <count group_id="B2" value="1101"/>
            <count group_id="B3" value="313"/>
            <count group_id="B4" value="2520"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="3.0"/>
                    <measurement group_id="B2" value="21.3" spread="2.9"/>
                    <measurement group_id="B3" value="22.2" spread="2.4"/>
                    <measurement group_id="B4" value="21.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1101"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1106"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="313"/>
                    <measurement group_id="B4" value="1419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine</title>
        <description>Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL</description>
        <time_frame>Four weeks post vaccination 3 (Month 7)</time_frame>
        <population>The analysis set includes heterosexual male and female participants who received the 3 vaccinations, were seronegative to the appropriate HPV type at baseline, and had Month 7 immunogenicity results for the appropriate HPV type. Per-protocol non-inferiority analysis compared heterosexual males and females only.</population>
        <group_list>
          <group group_id="O1">
            <title>Heterosexual Males</title>
            <description>Healthy heterosexual males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Females</title>
            <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>Men Who Have Sex With Men</title>
            <description>Healthy MSM 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine</title>
          <description>Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL</description>
          <population>The analysis set includes heterosexual male and female participants who received the 3 vaccinations, were seronegative to the appropriate HPV type at baseline, and had Month 7 immunogenicity results for the appropriate HPV type. Per-protocol non-inferiority analysis compared heterosexual males and females only.</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="914"/>
                <count group_id="O2" value="884"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6 (n=847, 708, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="782.0" lower_limit="738.0" upper_limit="828.7"/>
                    <measurement group_id="O2" value="703.9" lower_limit="660.6" upper_limit="749.9"/>
                    <measurement group_id="O3" value="568.9" lower_limit="498.7" upper_limit="649.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11 (n=851, 712, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616.7" lower_limit="582.4" upper_limit="653.0"/>
                    <measurement group_id="O2" value="564.9" lower_limit="530.6" upper_limit="601.3"/>
                    <measurement group_id="O3" value="437.7" lower_limit="384.4" upper_limit="498.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16 (n=899, 781, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3346.0" lower_limit="3158.9" upper_limit="3544.1"/>
                    <measurement group_id="O2" value="2788.3" lower_limit="2621.4" upper_limit="2965.8"/>
                    <measurement group_id="O3" value="2294.0" lower_limit="2037.8" upper_limit="2582.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18 (n=906, 831, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="808.2" lower_limit="754.9" upper_limit="865.4"/>
                    <measurement group_id="O2" value="679.8" lower_limit="633.1" upper_limit="730.1"/>
                    <measurement group_id="O3" value="608.1" lower_limit="529.4" upper_limit="698.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31 (n=908, 826, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="708.5" lower_limit="662.7" upper_limit="757.6"/>
                    <measurement group_id="O2" value="570.1" lower_limit="531.5" upper_limit="611.5"/>
                    <measurement group_id="O3" value="420.7" lower_limit="368.0" upper_limit="480.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33 (n=901, 853, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384.8" lower_limit="362.5" upper_limit="408.4"/>
                    <measurement group_id="O2" value="322.0" lower_limit="302.9" upper_limit="342.3"/>
                    <measurement group_id="O3" value="252.3" lower_limit="224.2" upper_limit="283.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45 (n=909, 871, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.6" lower_limit="219.0" upper_limit="253.6"/>
                    <measurement group_id="O2" value="185.7" lower_limit="172.3" upper_limit="200.2"/>
                    <measurement group_id="O3" value="157.5" lower_limit="136.2" upper_limit="182.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52 (n=907, 849, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.8" lower_limit="363.4" upper_limit="411.6"/>
                    <measurement group_id="O2" value="335.2" lower_limit="314.3" upper_limit="357.6"/>
                    <measurement group_id="O3" value="233.1" lower_limit="206.0" upper_limit="263.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58 (n=897, 839, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509.8" lower_limit="479.9" upper_limit="541.6"/>
                    <measurement group_id="O2" value="409.3" lower_limit="384.5" upper_limit="435.7"/>
                    <measurement group_id="O3" value="319.8" lower_limit="283.2" upper_limit="361.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used.</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 11</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 16</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 18</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 31</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 33</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 45</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 52</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 58</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to GMT ratio (heterosexual males / females) required that the lower bound of the 95% confidence interval was &gt;0.67, to exclude a decrease of 1.5-fold or more</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>An analysis of variance model with a response of log individual titers and fixed effect for group was used</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.</description>
        <time_frame>Up to 5 days after any vaccination</time_frame>
        <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Heterosexual and MSM Males</title>
            <description>Healthy heterosexual and MSM males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Females</title>
            <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.</description>
          <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1394"/>
                <count group_id="O2" value="1075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall injection-site AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection-site Erythema</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.0</ci_lower_limit>
            <ci_upper_limit>-8.0</ci_upper_limit>
            <estimate_desc>The incidence of AEs of injection-site erythema reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection-site Pain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-19.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.5</ci_lower_limit>
            <ci_upper_limit>-15.7</ci_upper_limit>
            <estimate_desc>The incidence of AEs of injection-site erythema reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection-site Swelling</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-17.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.8</ci_lower_limit>
            <ci_upper_limit>-13.7</ci_upper_limit>
            <estimate_desc>The incidence of AEs of injection-site erythema reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Elevated Oral Body Temperature (&gt;=37.8° C, &gt;=100° F)</title>
        <description>Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination</description>
        <time_frame>Up to 5 days after any vaccination</time_frame>
        <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Heterosexual and MSM Males</title>
            <description>Healthy heterosexual and MSM males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Females</title>
            <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Oral Body Temperature (&gt;=37.8° C, &gt;=100° F)</title>
          <description>Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination</description>
          <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
                <count group_id="O2" value="1066"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Elevated Body Temperature</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>The incidence of maximum body temperature &gt;=37.8° C reported on the Vaccination Report Card was compared between heterosexual / MSM male participants and female participants</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine</title>
        <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.</description>
        <time_frame>Four weeks post vaccination 3 (Month 7)</time_frame>
        <population>The analysis set includes participants who received the 3 vaccinations, were seronegative to the appropriate HPV type at baseline, and had Month 7 immunogenicity results for the appropriate HPV type. Per-protocol non-inferiority analysis compared heterosexual males and females only.</population>
        <group_list>
          <group group_id="O1">
            <title>Heterosexual Males</title>
            <description>Healthy heterosexual males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Females</title>
            <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>Men Who Have Sex With Men</title>
            <description>Healthy MSM 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine</title>
          <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.</description>
          <population>The analysis set includes participants who received the 3 vaccinations, were seronegative to the appropriate HPV type at baseline, and had Month 7 immunogenicity results for the appropriate HPV type. Per-protocol non-inferiority analysis compared heterosexual males and females only.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="914"/>
                <count group_id="O2" value="884"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV Type 6 (n=847, 708, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="99.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.6" lower_limit="98.8" upper_limit="99.9"/>
                    <measurement group_id="O3" value="99.4" lower_limit="96.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 11 (n=851, 712, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.6" upper_limit="100"/>
                    <measurement group_id="O2" value="99.9" lower_limit="99.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="97.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 16 (n=899, 781, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.6" upper_limit="100"/>
                    <measurement group_id="O2" value="99.9" lower_limit="99.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 18 (n=906, 831, 220)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="99.4" upper_limit="100"/>
                    <measurement group_id="O2" value="99.8" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O3" value="99.5" lower_limit="97.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 31 (n=908, 826, 227)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 33 (n=901, 853, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.6" upper_limit="100"/>
                    <measurement group_id="O2" value="99.9" lower_limit="99.3" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 45 (n=909, 871, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.2" upper_limit="100"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.8" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 52 (n=907, 849, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.6" upper_limit="100"/>
                    <measurement group_id="O2" value="99.8" lower_limit="99.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV Type 58 (n=897, 839, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.6" upper_limit="100"/>
                    <measurement group_id="O2" value="99.8" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 11</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 16</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 18</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 31</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 33</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 45</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 52</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV Type 58</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Criterion for non-inferiority with respect to seroconversion percentage (heterosexual males minus females) required that the lower bound of the 95% confidence interval was greater than -5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
        <time_frame>Up to Month 12</time_frame>
        <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Heterosexual and MSM Males</title>
            <description>Healthy heterosexual and MSM males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Females</title>
            <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
          <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1394"/>
                <count group_id="O2" value="1075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
        <time_frame>Up to Month 12</time_frame>
        <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Heterosexual and MSM Males</title>
            <description>Healthy heterosexual and MSM males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Females</title>
            <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.</description>
          <population>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1394"/>
                <count group_id="O2" value="1075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Month 12</time_frame>
      <desc>The analysis set includes all participants who received &gt;=1 vaccination and had safety follow-up. Heterosexual and MSM males were combined for safety outcomes.</desc>
      <group_list>
        <group group_id="E1">
          <title>Heterosexual and MSM Males</title>
          <description>Healthy heterosexual and MSM males 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E2">
          <title>Females</title>
          <description>Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Familial periodic paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>External ear cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Foetal malpresentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Schizophreniform disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1394"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1394"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="976" subjects_at_risk="1394"/>
                <counts group_id="E2" subjects_affected="924" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="422" subjects_affected="291" subjects_at_risk="1394"/>
                <counts group_id="E2" events="539" subjects_affected="348" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1877" subjects_affected="886" subjects_at_risk="1394"/>
                <counts group_id="E2" events="2101" subjects_affected="893" subjects_at_risk="1075"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="431" subjects_affected="285" subjects_at_risk="1394"/>
                <counts group_id="E2" events="661" subjects_affected="408" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="271" subjects_affected="200" subjects_at_risk="1394"/>
                <counts group_id="E2" events="378" subjects_affected="246" subjects_at_risk="1075"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

